Page last updated: 2024-11-09

tempo

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TEMPO: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

TEMPO : A member of the class of aminoxyls that is piperidine that carries an oxidanediyl group at position 1 and methyl groups at positions 2, 2, 6, and 6, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2724126
CHEMBL ID606971
CHEBI ID32849
MeSH IDM0045107

Synonyms (62)

Synonym
2,2,6,6-tetramethyl piperidine-n-oxyl
piperidinooxy, 2,2,6,6-tetramethyl-
1-piperidinyloxy, 2,2,6,6-tetramethyl-
2,2,6,6-tetramethylpiperidinooxy radical
2564-83-2
1,1,5,5-tetramethylpentamethylene nitroxide
(2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl
CHEBI:32849 ,
2,2,6,6-tetramethyl-1-piperidinyloxy
tempo
tetramethylpiperidinooxy
tetramethylpiperidine nitroxide
tanan
brn 1422418
einecs 219-888-8
tanane
2,2,6,6-tetramethylpiperidinyloxy
2,2,6,6-tetramethylpiperidinooxyl
2,2,6,6-tetramethylpiperidoxyl
tempo, purified by sublimation, 99%
tempo, 98%
2,2,6,6-tetramethylpiperidine 1-oxyl
T1560
CHEMBL606971
ccris 8316
unii-vqn7359icq
vqn7359icq ,
1-$l^{1}-oxidanyl-2,2,6,6-tetramethyl-piperidine
1-$l^{1}-oxidanyl-2,2,6,6-tetramethylpiperidine
A817947
2,2,6,6-tetramethylpiperidinooxy, free radical
BP-20268
FT-0609130
AKOS015902714
1-piperidinyloxy,2,2,6,6-tetramethyl-,
tempo [mi]
2,2,6,6-tetramethylpentamethylene nitroxide
4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl-
CCG-207968
Z-1024
DTXSID2073300
mfcd00009599
CS-W001187
tempo, free radical
205679-68-1
2,2,6,6-tetramethylpiperidine-d18-1-oxyl
126517-51-9
125012-91-1
2,2,6,6-tetramethylpiperidine-1-oxyl free radical, 98%
1-piperidinyloxy, 2,2,6,6-tetramethyl- (9ci)
25657-03-8
26933-82-4
2,2,6,6-tetramethylpiperindyl-1-oxide
2,2,6,6-tetramethylpiperidine 1-oxyl free radical
AMY23375
2,2,6,6-tetramethylpiperidine 1-oxyl, free radical - solid melt
2,2,6,6-tetramethyl-1-oxylpiperidine
(2,2,6,6-tetramethylpiperidin-1-yl)oxyl
HY-W001187
1-oxy-2,2,6,6-tetramethylpiperidine, free radical
EN300-125971
Z1255386734

Research Excerpts

Overview

Mito-TEMPO is a mitochondria-specific superoxide scavenger. TEMPO acts as a hydrogen transfer mediator and is either regenerated by oxygen or converted to TEMPH.

ExcerptReferenceRelevance
"Mito-TEMPO is a mitochondria-specific superoxide scavenger."( Hepatoprotective Effect of Mitochondria-Targeted Antioxidant Mito-TEMPO against Lipopolysaccharide-Induced Liver Injury in Mouse.
Cao, YX; Wang, PF; Xie, K; Zhang, A, 2022
)
1.41
"TEMPO acts as a hydrogen transfer mediator and is either regenerated by oxygen, under catalytic aerobic conditions, or converted to TEMPH under stoichiometric anaerobic conditions."( Efficient and selective aerobic oxidation of alcohols into aldehydes and ketones using ruthenium/TEMPO as the catalytic system.
Arends, IW; Dijksman, A; Mairata I Payeras, A; Marino-González, A; Sheldon, RA, 2001
)
1.25

Effects

Temporin-SHf has a highly hydrophobic sequence (FFFLSRIFa) and possesses the highest percentage of Phe residues of any known peptide or protein.

ExcerptReferenceRelevance
"Temporin-SHf has a highly hydrophobic sequence (FFFLSRIFa) and possesses the highest percentage of Phe residues of any known peptide or protein."( Temporin-SHf, a new type of phe-rich and hydrophobic ultrashort antimicrobial peptide.
Abbassi, F; Foulon, T; Goasdoué, N; Ladram, A; Lequin, O; Nicolas, P; Piesse, C, 2010
)
2.52
"TEMPO has earlier been quantified with electron paramagnetic resonance (EPR) spectroscopy."( A tandem mass spectrometric method for singlet oxygen measurement.
Huang, P; Karonen, M; Mamedov, F; Mattila, H; Styring, S; Tyystjärvi, E,
)
0.85
"TEMPO has been identified as a potential genotoxic impurity resulting in the need for analytical methodology to accurately determine its level at several orders of magnitude less than typical impurity quantitation limits."( Development of an LC-MS method for ultra trace-level determination of 2,2,6,6-tetramethylpiperidine-1-oxl (TEMPO), a potential genotoxic impurity within active pharmaceutical ingredients.
Boulineau, F; Cohen, RD; Pennington, J; Tian, Y, 2015
)
1.35
"Temporin-SHf has a highly hydrophobic sequence (FFFLSRIFa) and possesses the highest percentage of Phe residues of any known peptide or protein."( Temporin-SHf, a new type of phe-rich and hydrophobic ultrashort antimicrobial peptide.
Abbassi, F; Foulon, T; Goasdoué, N; Ladram, A; Lequin, O; Nicolas, P; Piesse, C, 2010
)
2.52

Actions

ExcerptReferenceRelevance
"TEMPO plays a key role in the formation of diaryl glycoside due to its radical nature."( TEMPO-Promoted Domino Heck-Suzuki Arylation: Diastereoselective Cis-Diarylation of Glycals and Pseudoglycals.
Bharatam, PV; Jaladanki, CK; Kusunuru, AK; Mukherjee, D; Tatina, MB, 2015
)
2.58

Treatment

Mito-TEMPO treatment increased survival of animals by 30%, decreased tumour incidence (25%) and tumour multiplicity (39%). Tempo-treated animals exhibited hair density values of approximately 90%. Treatment with Tempo did not affect the arterial pressure of un-operated normotensive rats.

ExcerptReferenceRelevance
"Mito-TEMPO treatment increased survival of animals by 30%, decreased tumour incidence (25%) and tumour multiplicity (39%). "( Mito-TEMPO, a mitochondria-targeted antioxidant, prevents N-nitrosodiethylamine-induced hepatocarcinogenesis in mice.
Bharati, S; Kumar, R; Shetty, S, 2019
)
1.54
"Mito-TEMPO treatment or MnSOD transfection also significantly prevented the LPS-induced increase of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α."( Mitochondrial reactive oxygen species mediate the lipopolysaccharide-induced pro-inflammatory response in human gingival fibroblasts.
Li, X; Luan, QX; Wang, X; Zheng, M, 2016
)
0.89
"Tempo-treated animals exhibited hair density values of approximately 90% compared with 12% in controls over weeks 11 to 14."( Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies.
Bonner, RF; Coffin, D; Cook, JA; Cuscela, D; Krishna, MC; Lupton, GP; Mitchell, JB,
)
0.85
"Tempo treatment (15 min) of MDA-MB 231 human breast cancer cells resulted in significant levels of tyrosine phosphorylation of several as yet unidentified proteins compared with equimolar concentration of tempol (10 mM)."( Nitroxides tempol and tempo induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells.
Ehleiter, D; Haimovitz-Friedman, A; Kasid, U; Mitchell, JB; Suy, S, 1998
)
1.41
"Treatment with Tempo did not affect the arterial pressure of un-operated normotensive rats but promptly decreased the arterial pressure of rats with aortic coarctation-induced hypertension (from 178 +/- 2 to 125 +/- 6 mmHg)."( Prostaglandin I2 does not contribute to the hypotensive effect of the superoxide dismutase mimetic Tempo in rats with aortic coarctation-induced hypertension.
DelliPizzi, A; Dinocca, S; Guan, H; Nasjletti, A, 2004
)
0.88
"Treatment with Tempo (10 mM, 37 degrees C/30 min) and hyperthermia (44 degrees C/30 min) induced 30 and 70-80% apoptosis, respectively, through Bax-mediated cytochrome c release and DEVDase activation."( Mechanism of cell death induction by nitroxide and hyperthermia.
Fujiwara, Y; Kondo, T; Zhao, QL, 2006
)
0.67

Toxicity

ExcerptReferenceRelevance
" HN2 was much less toxic to hepatocytes under nitrogen and caused much less lipid peroxidation than under aerobic conditions."( Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation.
Khan, S; O'Brien, PJ; Ramwani, JJ, 1992
)
0.28
" Irreversible cardiomyopathy is a serious and dose-limiting side effect after chronic administration."( Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Bast, A; van Acker, SA; van Asbeck, BS; van der Vijgh, WJ; Voest, EE, 1994
)
0.29
" The results clearly confirmed that the toxic effect could result either from the presence or structure of substituent(s) at position 4 of the free radical piperidine moiety."( Tempicol-3, a novel piperidine-N-oxide stable radical and antioxidant, with low toxicity acts as apoptosis inducer and cell proliferation modifier of Yoshida Sarcoma cells in vivo.
Gwoździnski, K; Głebska, J; Jóźwiak, Z; Koceva-Chyła, A; Kochman, A; Metodiewa, D,
)
0.13
" In general, RGD-oxidized starch nanoassemblies showed a great potential as a new type of safe and effective nanocarrier for anti-cancer therapy."( TEMPO-oxidized starch nanoassemblies of negligible toxicity compared with polyacrylic acids for high performance anti-cancer therapy.
Jiang, Y; Li, D; Li, T; Li, Y; Lu, M; Ren, F; Zhao, H, 2018
)
1.92
" Pretreatment of mito-TEMPO protected animals from toxic effects of BPA as indicated by the normalization of sperm parameters and preserved histoarchitecture of testis."( Mito-TEMPO protects against bisphenol-A-induced testicular toxicity: an in vivo study.
Bharati, S; Kumar, V; Ramesh, V; Shetty, S,
)
0.96

Compound-Compound Interactions

ExcerptReferenceRelevance
"Results showed that the optimal eye formulation contained PRP activated by 350 μg/mL of the low-molecular-weight chitosan group (L3) combined with 300 μg/mL TO50SC (L3+T050SC)."( TEMPO-Oxidized Sacchachitin Nanofibers (TOSCNFs) Combined with Platelet-Rich Plasma (PRP) for Management of Dry Eye Syndrome.
Chao, FC; Chen, LC; Ho, HO; Lin, HL; Liu, DZ; Sheu, MT; Wu, MH; Wu, TH, 2020
)
2

Bioavailability

ExcerptReferenceRelevance
"In skeletal muscle arterioles of normotensive rats fed a high salt diet, the bioavailability of endothelium-derived nitric oxide (NO) is reduced by superoxide anion."( High salt intake reduces endothelium-dependent dilation of mouse arterioles via superoxide anion generated from nitric oxide synthase.
Boegehold, MA; Nurkiewicz, TR, 2007
)
0.34
"Because issues of cost and bioavailability have hampered the development of gene-encoded antimicrobial peptides to combat infectious diseases, short linear peptides with high microbial cell selectivity have been recently considered as antibiotic substitutes."( Temporin-SHf, a new type of phe-rich and hydrophobic ultrashort antimicrobial peptide.
Abbassi, F; Foulon, T; Goasdoué, N; Ladram, A; Lequin, O; Nicolas, P; Piesse, C, 2010
)
1.8

Dosage Studied

ExcerptRelevanceReference
" Male Sprague-Dawley rats were dosed with two doses of metronidazole (50 mg/kg, 12 and 1 h pre-NSAID) or a single 100 mg/kg dose of tempo 1 h prior to NSAIDs."( Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers.
Davies, NM; Jamali, F, 1997
)
0.72
" When added to a slurry of unbleached softwood kraft fibers, in combination with an optimal dosage of aluminum sulfate, the oxidized β-D-glucan yielded greater increases in tensile strength and folding endurance in comparison to untreated β-D-glucan."( TEMPO-mediated oxidation of oat β-D-glucan and its influences on paper properties.
Hubbe, MA; Song, X, 2014
)
1.85
" Fibril dosage and oxidation degree exerted a great influence on the stability and particle size distribution of emulsion samples."( Surfactant-free emulsions stabilized by tempo-oxidized bacterial cellulose.
Fu, W; Jia, Y; Li, F; Liu, Y; Zhai, X; Zhong, C, 2016
)
0.7
" In addition to dosing reagents by means of a low-cost peristaltic pump, we also present carefully controlled dosing of reagents by an open-source syringe pump."( "Do-It-Yourself" reliable pH-stat device by using open-source software, inexpensive hardware and available laboratory equipment.
Kostic, M; Kragic, R; Milanovic, JZ; Milanovic, P, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
catalystA substance that increases the rate of a reaction without modifying the overall standard Gibbs energy change in the reaction.
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
piperidines
aminoxylsRadicals derived from hydroxylamines by removal of the hydrogen atom from the hydroxy group. The synonymous terms nitroxyl radicals and nitroxides erroneously suggest the presence of a nitro group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID572090Antimalarial activity against Plasmodium falciparum NF54 by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID572091Antimalarial activity against Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals.
AID1301297Antioxidant activity assessed as ABTS radical scavenging activity after 60 mins2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Enantioselective synthesis and antioxidant activity of 3,4,5-substituted piperidine derivatives.
AID644747Cytotoxicity against human A431 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents.
AID216890Mean surviving fraction of V79 cells following a 1-h exposure to H2O2.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID644748Cytotoxicity against human A431 cells at 300 uM after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents.
AID216900Mean surviving fraction of V79 cells following a 12-Gy dose of radiation.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (930)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (4.19)18.7374
1990's119 (12.80)18.2507
2000's227 (24.41)29.6817
2010's418 (44.95)24.3611
2020's127 (13.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 149.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index149.93 (24.57)
Research Supply Index6.87 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index282.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (149.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (0.73%)5.53%
Reviews22 (2.31%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other925 (96.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label Study to Assess the Safety and Clinical Efficacy of MBM-02 to Increase Survival in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) [NCT04874506]Phase 255 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Extending the Prerogatives of Colorectal Cancer Screening French Organizations to the Follow-up After Colonoscopy of Patients Aged 50 or More: Pilot Study in the Rhône Administrative Department [NCT03383367]33,000 participants (Anticipated)Interventional2017-08-24Enrolling by invitation
The Effects of Moviprep With Simethicone on Colonic Bubbles [NCT01209806]140 participants (Actual)Interventional2009-11-30Completed
Assessment of Participant Adherence and Glucose Control While Using a Connected Insulin Management Platform [NCT05893797]100 participants (Anticipated)Interventional2023-10-05Recruiting
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment in Breast Cancer [NCT04803084]10 participants (Anticipated)Observational2021-08-09Suspended(stopped due to MRI upgrade)
A Phase 1, Open-Label, 3-Period Crossover Study Of The Effect Of An Antacid, A Proton Pump Inhibitor And An H2-Receptor Antagonist On Palbociclib (PD-0332991) Bioavailability Under Fed Conditions In Healthy Volunteers [NCT02097329]Phase 127 participants (Actual)Interventional2014-04-30Completed
Reducing Anxiety and Enhancing Quality of Life Among Caregivers of Prostate Cancer Survivors: Development and Evaluation of a Dyadic, Tailored, Web-based, Psychosocial and Physical Activity Self-management Programme [NCT04304196]82 participants (Actual)Interventional2020-06-01Completed
The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment - II [NCT02946060]169 participants (Actual)Interventional2016-02-29Completed
The Effects of Virtual Low-Tempo and High-Tempo Zumba® in Individuals With Developmental Disabilities on Functional Mobility, Aerobic Capacity, Inhibitory Control, Attention, and Balance [NCT05198232]57 participants (Actual)Interventional2021-01-26Completed
Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers [NCT00944307]Phase 117 participants (Actual)Interventional2009-07-31Completed
An Open-Label, 3-Period, Fixed-Sequence, Study to Examine the Effect of Aluminum Hydroxide/Magnesium Hydroxide/Simethicone and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects [NCT04368585]Phase 120 participants (Actual)Interventional2020-07-01Completed
An Open Label, Dose Comparison Study to Assess the Efficacy of MBM-02 (Tempol) as a Treatment for Patients Diagnosed With Prostate Cancer in Biochemical Recurrence [NCT04876755]Phase 255 participants (Anticipated)Interventional2021-05-30Not yet recruiting
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy [NCT03480971]Phase 2120 participants (Anticipated)Interventional2019-05-13Recruiting
Treatment of Meniscal Problems in Osteoarthritis [NCT03059004]860 participants (Anticipated)Interventional2018-02-06Recruiting
Decreasing Delirium Through Music in Critically Ill Older Adults [NCT04182334]160 participants (Anticipated)Interventional2020-03-05Recruiting
A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer [NCT04337099]0 participants Expanded AccessAvailable
Prevention of Teen Pregnancy Through Screening and Brief Intervention in Primary Care [NCT02816424]447 participants (Actual)Interventional2015-11-11Completed
A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen [NCT01622673]Phase 127 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01622673 (8) [back to overview]Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)
NCT01622673 (8) [back to overview]Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)
NCT01622673 (8) [back to overview]Least Squares Mean Steady State Area Under the Plasma Concentration-Time (AUC0-12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)
NCT01622673 (8) [back to overview]Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)
NCT01622673 (8) [back to overview]Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)
NCT01622673 (8) [back to overview]Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)
NCT01622673 (8) [back to overview]Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir
NCT01622673 (8) [back to overview]Number of Participants With Any Clinical or Laboratory Adverse Event (AE)

Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)

Participant blood samples were collected to measure the steady state maximum plasma concentration of raltegravir when administered alone or with a single dose of antacid. The primary hypothesis compared Cmax of raltegravir when administered alone with Cmax of raltegravir when coadministered with TUMS® or MINTOX®. (NCT01622673)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose

InterventionnM (Least Squares Mean)
Raltegravir5427.15
TUMS® + Raltegravir2584.78
MINTOX® + Raltegravir3013.88

[back to top]

Least Squares Mean Maximum Plasma Concentration (Cmax) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)

Participant blood samples were collected to measure the maximum steady state plasma concentration of raltegravir after administration alone or before or after a single dose of antiacid. The secondary hypothesis compared Cmax of raltegravir when administered alone with Cmax of raltegravir when administered 2 hours before or after MINTOX®. (NCT01622673)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose

InterventionnM (Least Squares Mean)
Raltegravir5678.90
MINTOX® Before Raltegravir2753.64
MINTOX® After Raltegravir4399.66

[back to top]

Least Squares Mean Steady State Area Under the Plasma Concentration-Time (AUC0-12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)

Participant blood samples were collected to measure the steady state AUC of raltegravir up to 12 hours after administration alone or before or after a single dose of antacid. The secondary hypothesis compared AUC0-12hrs of raltegravir when administered alone with AUC0-12hrs of raltegravir when administered 2 hours before or after MINTOX®. (NCT01622673)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose

InterventionnM*hr (Least Squares Mean)
Raltegravir17577.15
MINTOX® Before Raltegravir8521.95
MINTOX® After Raltegravir12226.11

[back to top]

Least Squares Mean Steady State Area Under the Plasma Concentration-time Curve (AUC0-12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)

Participant blood samples were collected to measure the steady state AUC of raltegravir up to 12 hours after administration alone or with a single dose of antacid. The primary hypothesis compared AUC0-12hrs of raltegravir when administered alone with AUC0-12hrs of raltegravir when coadministered with TUMS® or MINTOX®. (NCT01622673)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose

InterventionnM*hr (Least Squares Mean)
Raltegravir16399.76
TUMS® + Raltegravir7294.30
MINTOX® + Raltegravir8358.67

[back to top]

Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Coadministration of Antacid (Primary Hypothesis)

Participant blood samples were collected to measure the steady state plasma concentration of raltegravir 12 hours after administration alone or with a single dose of antacid. The primary hypothesis compared C12hrs of raltegravir when administered alone with C12hrs of raltegravir when coadministered with TUMS® or MINTOX®. (NCT01622673)
Timeframe: 12 hours postdose

InterventionnM (Least Squares Mean)
Raltegravir132.30
TUMS® + Raltegravir89.75
MINTOX® + Raltegravir49.38

[back to top]

Least Squares Mean Steady State Plasma Concentration (C12hrs) of Raltegravir After Staggered Administration of Antacid (Secondary Hypothesis)

Participant blood samples were collected to measure the steady state plasma concentration of raltegravir 12 hours after administration alone or before or after a single dose of antacid. The secondary hypothesis compared C12hrs of raltegravir when administered alone with C12hrs of raltegravir when administered 2 hours before or after MINTOX®. (NCT01622673)
Timeframe: 12 hours postdose

InterventionnM (Least Squares Mean)
Raltegravir125.75
MINTOX® Before Raltegravir54.92
MINTOX® After Raltegravir54.47

[back to top]

Mean Time to Maximum Plasma Concentration (Tmax) of Raltegravir

Participant blood samples were collected to measure the time to achieve the maximum steady state plasma concentration of raltegravir when administered alone or with a single dose of antacid (NCT01622673)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose

Interventionhr (Mean)
Raltegravir2.06
TUMS® + Raltegravir2.08
MINTOX® + Raltegravir1.48
MINTOX® Before Raltegravir1.52
MINTOX® After Raltegravir1.78

[back to top]

Number of Participants With Any Clinical or Laboratory Adverse Event (AE)

"An AE is defined as any unfavorable and unintended change in the~structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience." (NCT01622673)
Timeframe: Up to 7 days after the last dose of study drug

Interventionparticipants (Number)
Raltegravir1
TUMS® + Raltegravir2
MINTOX® + Raltegravir2
MINTOX® Before Raltegravir2
MINTOX® After Raltegravir1

[back to top]